Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
134.67
+2.61 (+1.98%)
Streaming Delayed Price
Updated: 3:22 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
Today 12:50 EDT
Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. The telehealth...
Via
Benzinga
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Today 10:04 EDT
Via
Benzinga
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Today 6:50 EDT
This strategic play will take time to pay off, but it could keep growth going.
Via
The Motley Fool
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
September 18, 2024
Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...
Via
Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Telemedicine once seemed like it was going to revolutionize healthcare.
Via
The Motley Fool
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,700 Today
September 11, 2024
Via
Benzinga
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
September 09, 2024
Via
Benzinga
What the Options Market Tells Us About Novo Nordisk
September 06, 2024
Via
Benzinga
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
September 14, 2024
No need to break the bank to get in on these excellent companies.
Via
The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
September 13, 2024
The major indexes reclaimed key levels and many leaders flashed buy signals.
Via
Investor's Business Daily
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
September 12, 2024
An investment in these players today could score a big win down the road.
Via
The Motley Fool
Novo Nordisk Unusual Options Activity
September 05, 2024
Via
Benzinga
Why Roche Holdings Stock Withered on Wednesday
September 11, 2024
The company had a dispiriting update to offer about an investigational drug.
Via
The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
September 11, 2024
The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.
Via
The Motley Fool
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
September 11, 2024
The company is working on a drug that targets GLP-1 and amylin to improve weight loss.
Via
Investor's Business Daily
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
September 11, 2024
Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight loss in three months with adult participants.
Via
Benzinga
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.
Via
The Motley Fool
Exposures
COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
September 11, 2024
Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children...
Via
Benzinga
Exposures
Product Safety
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
September 07, 2024
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?
Via
MarketBeat
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
September 07, 2024
The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock.
Via
The Motley Fool
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
September 05, 2024
Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.
Via
Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
September 05, 2024
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.
Via
Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
September 05, 2024
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges.
Via
Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
September 05, 2024
Lilly just lowered the price of Zepbound.
Via
The Motley Fool
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
September 05, 2024
Could this beaten-down stock turn things around in the near future?
Via
The Motley Fool
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
September 05, 2024
For those who appreciate growth without the sticker shock, NYSE:NVO is worth considering.
Via
Chartmill
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
September 04, 2024
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...
Via
Benzinga
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
September 04, 2024
The companies are well-known for their obesity treatments and could reach a $1 trillion market cap before carmaker Tesla.
Via
Investor's Business Daily
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
September 04, 2024
BioAge Labs a biotech company focused on therapies for metabolic diseases, has filed for a $100 million IPO. Founded in 2015, the company plans to list on Nasdaq under the symbol BIOA. Their lead drug,...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.